Lanwei Medical (301060.SZ): A total cost of 15.3867 million yuan to buy back 1.1612,000 shares

Gelonghui, April 2, 丨 Lan Wei Medical (301060.SZ) announced that as of March 31, 2024, the company had repurchased a total of 1.1612 million shares through the Shenzhen Stock Exchange stock trading system, accounting for 0.29% of the company's current total share capital. The highest transaction price was 14.23 yuan/share, the minimum transaction price was 9.69 yuan/share, and the total transaction amount was RMB 15.3867 million (excluding transaction fees).

Gelonghui FinanceApr 2 04:46 ET

Further Upside For Shanghai Labway Clinical Laboratory Co., Ltd (SZSE:301060) Shares Could Introduce Price Risks After 43% Bounce

Shanghai Labway Clinical Laboratory Co., Ltd (SZSE:301060) shareholders would be excited to see that the share price has had a great month, posting a 43% gain and recovering from prior weakness. Un

Simply Wall StMar 20 18:47 ET

Investors Will Want Shanghai Labway Clinical Laboratory's (SZSE:301060) Growth In ROCE To Persist

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly,

Simply Wall StFeb 28 00:45 ET

Lanwei Medical (301060.SZ): A total cost of 14.9986 million yuan to buy back 0.28% of the shares

Gelonghui, Feb. 2: Lanwei Medical (301060.SZ) announced that as of January 31, 2024, the company had repurchased 1,121,200 shares of the company's shares through centralized bidding transactions through the Shenzhen Stock Exchange stock trading system, accounting for 0.28% of the company's current total share capital. The highest transaction price was 14.23 yuan/share, the minimum transaction price was 12.75 yuan/share, and the total transaction amount was RMB 14,998,563.00.

Gelonghui FinanceFeb 2 04:35 ET

Investors Give Shanghai Labway Clinical Laboratory Co., Ltd (SZSE:301060) Shares A 27% Hiding

Shanghai Labway Clinical Laboratory Co., Ltd (SZSE:301060) shareholders that were waiting for something to happen have been dealt a blow with a 27% share price drop in the last month. For any long-

Simply Wall StJan 31 17:35 ET

Lanwei Medical (301060.SZ): Pre-loss of 110 million yuan to 165 million yuan in 2023

Gelonghui, January 30, 丨 Lanwei Medical (301060.SZ) announced the 2023 annual results forecast. The net profit loss attributable to shareholders of listed companies during the reporting period was RMB 110 million to RMB 165 million, with a profit of RMB 617.328 million for the same period last year; net profit loss after deducting non-recurring profit and loss of RMB 124 million - RMB 185 million, and profit of RMB 644.4795 million. Reasons for changes in performance: 1. During the reporting period, due to a decrease in testing demand, the medical diagnosis service business revenue declined significantly, causing the company's net profit to decline. 2. Partial inspection of business accounts receivable

Gelonghui FinanceJan 30 03:14 ET